FCM
BPMC

Frontier Capital Management’s Blueprint Medicines BPMC Stock Holding History

Frontier Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,687
Closed -$2.78M – 299
2025
Q2 		$2.78M Sell
21,687
-21,297
-50% -$2.21M 0.03% 283
2025
Q1 		$3.8M Sell
42,984
-62,146
-59% -$6.06M 0.04% 262
2024
Q4 		$9.17M Buy
105,130
+84,171
+402% +$7.71M 0.09% 226
2024
Q3 		$1.94M Sell
20,959
-164,569
-89% -$16.3M 0.02% 263
2024
Q2 		$20M Buy
185,528
+64,029
+53% +$6.41M 0.2% 173
2024
Q1 		$11.5M Buy
121,499
+63,032
+108% +$5.41M 0.11% 208
2023
Q4 		$5.39M Buy
+58,467
New +$3.79M 0.05% 229

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Frontier Capital Management's BPMC Position: Q3 2025 in Review

Frontier Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 21,687 shares — an estimated $2.78M sold.

Frontier Capital Management first reported a position in BPMC in Q4 2023 and held it in 7 quarters. The position peaked at $20M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Frontier Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Frontier Capital Management sold 21,687 Blueprint Medicines shares in Q3 2025, an estimated $2.78M.
  • Frontier Capital Management first reported a position in Blueprint Medicines in Q4 2023 and held it in 7 quarters.
  • Frontier Capital Management's Blueprint Medicines position peaked at $20M in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Frontier Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.